Mystic Ventures
Mystic Ventures is an early-stage venture capital firm based in Los Angeles that invests in neuropsychiatric and CNS therapies and companies advancing the expansion of human consciousness. Founded in 2021, Mystic Ventures supports pre-seed and seed-stage startups developing psychedelic medicines, mental health treatments, and related cognitive health innovations. The firm leverages a broad network across medical professionals, academia, and the investment community to validate startup theses and access deal flow, while pursuing high-quality, scientifically grounded ventures. Mystic Ventures aims to accelerate the clinical and commercial development of therapies addressing mental health and neurological conditions.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Mental Health
Xylo Bio
Seed Round in 2024
Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.
Spiritus Bioscience
Venture Round in 2023
Spiritus Bioscience is a biotechnology company focused on developing novel psychedelic therapeutics. It specializes in proprietary drug-delivery technologies aimed at enhancing patient experience and safety in mental health treatments, with a current focus on Medicalized-Psilocybin in Oregon.
Awakn Life Sciences
Post in 2023
Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.
Heading Health
Venture Round in 2023
Heading Health is a technology-driven platform enhancing access to affordable mental health care. It offers personalized treatment solutions, combining evidence-based therapeutics with advanced technologies like transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine.
Journey Clinical
Series A in 2023
Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.
Enthea
Seed Round in 2022
Enthea facilitates access to safe and affordable psychedelic-assisted therapies as an employee benefit. It connects businesses with certified practitioners for Ketamine-Assisted Therapy and Psychedelic-Assisted Therapy, offering workplace plans that cover these critical mental health treatments.
Spiritus Bioscience
Seed Round in 2022
Spiritus Bioscience is a biotechnology company focused on developing novel psychedelic therapeutics. It specializes in proprietary drug-delivery technologies aimed at enhancing patient experience and safety in mental health treatments, with a current focus on Medicalized-Psilocybin in Oregon.
Beckley Retreats
Seed Round in 2022
Beckley Retreats is a provider of virtual integration programs designed to support individuals with neurological and psychiatric disorders. The company specializes in facilitating safe and legal psychedelic retreats that offer scientific insights into healing practices. Beckley Retreats emphasizes holistic training and dedicated care, ensuring that participants have access to necessary medical support. Additionally, the company provides training and certification programs for practitioners, equipping them with the skills needed to guide others through their healing journeys.
Maya Health
Seed Round in 2022
Naitur.ai is a company focused on enhancing psychedelic healthcare through a specialized practice management platform. Founded in 2019 and based in Denver, Colorado, the platform allows practitioners to track, manage, and measure health outcomes effectively. It offers personalized protocols and psychedelic-specific assessments that help in monitoring dosages, wellness outcomes, and psychological metrics. By streamlining these processes, Naitur.ai aims to reduce the workload for psychedelic practitioners, enabling them to serve a larger number of clients and improve mental health and well-being in the communities they support.
Journey Clinical
Series A in 2022
Journey Clinical offers an online platform that supports independent psychotherapists in expanding their practices to include ketamine-assisted psychotherapy. The company facilitates prescription services, enabling mental health professionals to provide safe and effective psychedelic therapy to patients.
Heading Health
Seed Round in 2022
Heading Health is a technology-driven platform enhancing access to affordable mental health care. It offers personalized treatment solutions, combining evidence-based therapeutics with advanced technologies like transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine.
Heading Health
Series A in 2022
Heading Health is a technology-driven platform enhancing access to affordable mental health care. It offers personalized treatment solutions, combining evidence-based therapeutics with advanced technologies like transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine.
Stillmind Therapeutics
Pre Seed Round in 2022
Stillmind is a precision neuroscience company focused on targeted small molecule discovery for treating brain disorders. It employs AI-enabled technology and biology-first principles to develop medicines tailored to molecular patient subtypes, initially targeting bipolar disorder.
Breathwrk
Funding Round in 2022
Breathwrk develops a mobile application offering science-backed guided breathing exercises. Users can manage mental wellness by reducing anxiety, improving sleep, enhancing focus, and boosting energy.
FireflyVR
Seed Round in 2022
FireflyVR specializes in developing innovative Virtual Reality (VR) experiences aimed at positively impacting physical health, mental well-being, education, and research. Their flagship product, The Sanctuary, is a clinically designed VR solution that prepares patients for transformative ketamine treatments by incorporating cognitive behavioral therapy techniques to reduce anxiety and enhance therapeutic outcomes.
Lykos Therapeutics
Funding Round in 2022
Lykos Therapeutics aims to transform mental health treatment by developing innovative medicines and therapies assisted by psychedelics. With over three decades of experience, they focus on rigorous scientific research to create novel therapeutic options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.